Expression Therapeutics Awarded NCI SBIR Grant to Advance ET501, a PTK7-Targeted γδ T-Cell Therapy for Children with High-Risk Neuroblastoma
National Cancer Institute (NCI) Small Business Innovation Research (SBIR) award funds development of ET501 toward an Investigational New Drug application ATLANTA, Oct. 15, 2026 /PRNewswire/ -- Expression Therapeutics, Inc., a clinical-stage gene and cell therapy company, today announced...